U.S. vaccine advisers are assembly to think about whether or not to alter suggestions on using
Johnson & Johnson’s
JNJ 0.95%
Covid-19 vaccine due to the chance of a uncommon however critical blood-clotting situation.
The Advisory Committee on Immunization Practices is listening to updates from Facilities for Illness Management and Prevention officers on studies of J&J vaccine recipients experiencing blood clots mixed with low blood-platelet ranges.
The committee is anticipated to vote Thursday afternoon on whether or not to replace its advice on use of the J&J vaccine, in accordance with an agenda posted on-line by the CDC.
Earlier this 12 months, federal well being authorities paused using J&J’s vaccine whereas they investigated the uncommon situation, often known as thrombosis with thrombocytopenia syndrome, or TTS. Use of the vaccine resumed in April after well being authorities concluded its advantages nonetheless outweighed the dangers.
The ACIP, which advises the CDC on vaccine coverage, voted in April to renew use of J&J’s vaccine, after assembly twice to debate the problem. Warnings concerning the danger have been added to truth sheets given to vaccine suppliers and recipients, together with that the chance appeared highest amongst ladies ages 30 to 49.
At the moment, a complete of 15 instances of TTS had been reported amongst practically 7 million vaccine doses administered. The entire instances occurred in ladies between the ages of 18 and 59, with a median age of 37 years. Signs developed between six and 15 days after vaccination.
Partly due to the protection considerations, J&J’s single-dose vaccine has been used a lot lower than the two-dose vaccines from
Moderna Inc.
MRNA -0.87%
and
Pfizer Inc.
PFE 2.98%
with its accomplice
BioNTech SE.
About 16.1 million folks within the U.S. have acquired J&J’s vaccine, in accordance with the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.
J&J stated in an announcement Thursday it not too long ago up to date the very fact sheet for its vaccine to say that it shouldn’t be administered to individuals who beforehand skilled TTS after receiving a previous dose of both the J&J vaccine or different vaccines with an analogous adenovirus-based design.
Different photographs with an analogous design embody
AstraZeneca
PLC’s Covid-19 vaccine, which is accessible exterior the U.S. however not within the U.S.
Write to Peter Loftus at peter.loftus@wsj.com
Copyright ©2021 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
